## MCK: McKesson Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.12 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($778.52)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. McKesson Corporation $MCK Shares Sold by Lombard Odier Asset Management USA Corp**
- Source: MarketBeat | 20251209T133143 | Neutral | Relevance: 99%
-  Lombard Odier Asset Management USA Corp significantly reduced its stake in McKesson Corporation (NYSE:MCK) by 57.8% in the second quarter, selling over 4,200 shares. Despite this, several other institutional investors, including Norges Bank and Nuveen LLC, purchased new stakes or increased their holdings in McKesson during recent quarters. Analysts hold a "Moderate Buy" rating for McKesson with a consensus target price of $892.86.

**2. Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna Invests $1.87 Million in McKesson Corporation $MCK**
- Source: MarketBeat | 20251209T134343 | Bullish | Relevance: 97%
-  Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna recently acquired a new stake of 2,552 shares, valued at approximately $1.87 million, in McKesson Corporation (NYSE:MCK). This investment is part of a broader trend where institutional investors and hedge funds own 85.07% of McKesson's stock, alongside recent adjustments in holdings by other investment firms. McKesson has also received favorable analyst ratings and recently announced a quarterly dividend, indicating ongoing investor confidence and strong financial performance.

**3. Is Cardinal Health Still Attractively Priced After Its Huge 2025 Run And DCF Upside?**
- Source: Simply Wall Street | 20251211T160826 | Somewhat-Bullish | Relevance: 65%
-  Cardinal Health (NYSE:CAH) has seen significant stock appreciation in 2025 but, according to a Discounted Cash Flow (DCF) analysis, its shares are still trading at a 57.1% discount to their estimated fair value. While its Price to Earnings (PE) ratio of 29.5x is slightly above the industry average, it aligns closely with Simply Wall St's proprietary "Fair Ratio" of 29.1x, suggesting the stock is priced appropriately based on current earnings. The article encourages investors to use "Narratives" for a more nuanced valuation, considering differing perspectives on future revenue and risks.

**4. Employers Rank Health Care Cost Control as No. 1 Priority**
- Source: planadviser | 20251209T120423 | Somewhat-Bullish | Relevance: 64%
- Employers are prioritizing health care cost control as their top strategic objective for 2026, surpassing talent attraction and retention. This shift is driven by a "volatile cost environment" including chronic conditions and rising medical/pharmacy prices. The article highlights strategies such as evaluating medical stop-loss plans and digital health solutions, and discusses the impact of GLP-1 medications and the emergence of direct-to-consumer drug sales to manage costs.

**5. Precision Medicine Software Market to Hit USD 5.25 Billion**
- Source: openPR.com | 20251209T065408 | Somewhat-Bullish | Relevance: 63%
-  The global Precision Medicine Software Market is projected to reach US$ 5.25 billion by 2033, growing at a CAGR of 12.1% from US$ 1.89 billion in 2024. This growth is driven by the increasing demand for personalized healthcare solutions and advancements in genomic sequencing and big data analytics. North America currently leads the market, while Asia-Pacific is rapidly emerging as a high-growth region.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $960 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.3%)
- Blackrock Inc.: 9.2% (+0.4%)
- State Street Corpora: 4.7% (+0.9%)
- JPMORGAN CHASE & CO: 4.5% (+16.0%)
- Massachusetts Financ: 3.2% (-1.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.12 suggests fair value with growth premium. Balance sheet: $2.3B free cash flow. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $101.4B |
| Beta | 0.38 |
| 52W Range | $558.13 - $895.58 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.12 |
| Forward P/E | 18.6 |
| Current P/E | 21.1 |
| YoY Growth | 13.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -7.2% to -5.2% (+1.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 9.2pp (needs >4.0% for momentum thesis). MRS_5 turning positive (1.2%) - potential reversal signal. AM_20 at -3.1% indicates price below own 20MA trend. Long-term uptrend intact (above SMA200 at 1.12x) but short-term weakness (below SMA20). MACD histogram bearish (-8.05), momentum weakening. RSI neutral at 46.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -5.22% (CS: 10) | Weak |
| RSI_14 | 45.6 | Neutral |
| MACD Histogram | -8.05 | Bearish |
| vs SMA20 | 0.969x | Below |
| vs SMA50 | 0.999x | Below |
| vs SMA200 | 1.122x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $815.54
- **Stop Loss:** $778.52 (4.5% risk)
- **Target:** $889.58 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 37
- **Position Value:** $30,174.98
- **Portfolio %:** 30.17%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-04 (Est: $9.28)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.05 | $9.86 | +8.9% |
| 2025Q2 | $8.15 | $8.26 | +1.4% |
| 2025Q1 | $9.83 | $10.12 | +3.0% |
| 2024Q4 | $7.99 | $8.03 | +0.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*